Description: <p><b>Eugenol</b> — Eugenol is a naturally occurring phenylpropanoid and volatile aromatic phenol most strongly associated with clove oil from <i>Syzygium aromaticum</i>. Eugenol is a phenolic aromatic ingredient that is chiefly derived from clove oil. It is formally classified as a small-molecule phytochemical, essential-oil constituent, food-flavouring agent, and experimental anticancer adjunct rather than an approved oncology drug. Standard abbreviations include EUG and 4-allyl-2-methoxyphenol. It is also present in cinnamon, basil, bay, nutmeg, and other aromatic plants. The oncology evidence is mainly preclinical, with strongest support for apoptosis induction, PI3K/Akt suppression, anti-metastatic effects, and chemo/radiosensitization in cell and animal models. clove oil has been advertised as a dental pain-relieving agent and germicide, and is used in mouthwashes and pharmaceutical drugs. Eugenol (4-allyl (-2-mthoxyphenol)), a phenolic natural compound available in honey and in the essential oils of different spices such as Syzgium aromaticum (clove), Pimenta racemosa (bay leaves), and Cinnamomum verum (cinnamon leaf).<br>
-eugenol is the major ingredient of three spices (i.e. clove, cinnamon,and nutmeg)<br>
-clear to pale yellow liquid with an oily consistency and a spicy aroma. It is sparingly soluble in water and well soluble in organic solvents. <br>
-entering the systemic circulation within 30-60 minutes, paradoxically limits it therapeutic effectiveness.
</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Induction of intrinsic and extrinsic apoptosis through mitochondrial dysfunction, Bax/Bcl-2 shift, cytochrome-c release, caspase activation, and PARP cleavage.</li>
<li>Suppression of PI3K/Akt/mTOR and related survival signalling, including FOXO3a-linked autophagy/apoptosis in breast cancer models.</li>
<li>Anti-inflammatory transcriptional modulation, especially ↓ NF-κB, ↓ COX-2, ↓ inflammatory cytokine signalling, and context-dependent STAT3/IL-6 axis suppression.</li>
<li>Anti-metastatic and anti-invasive activity through ↓ MMP-2/MMP-9, ↓ migration, ↓ invasion, and reduced epithelial-mesenchymal transition markers in selected models.</li>
<li>Anti-angiogenic effects through ↓ VEGF-linked signalling and reduced invasion/angiogenesis markers in gastric and other cancer models.</li>
<li>ROS redox modulation with model-dependent pro-oxidant stress in cancer cells and antioxidant/anti-inflammatory effects in non-malignant contexts.</li>
<li>Chemosensitization and radiosensitization, reported preclinically with cisplatin, gemcitabine, and ionizing radiation, but not clinically established.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Eugenol is rapidly absorbed and extensively metabolized, mainly through conjugation pathways, so systemic exposure is transient and formulation-dependent. Its volatility, lipophilicity, rapid metabolism, and local irritation risk make delivery strategy important. Nanoemulsions, encapsulation, and conjugated delivery systems are being explored preclinically to improve stability, exposure, and tumour delivery.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Many in-vitro anticancer studies use micromolar-to-high-micromolar concentrations that may exceed freely achievable systemic exposure after ordinary dietary or flavouring-level intake. Low-dose mechanistic reports exist in some breast cancer models, but translation remains uncertain. Essential-oil or clove-derived exposure should not be equated with purified eugenol pharmacology because source composition, dose, and route strongly affect exposure.</p>
<p><b>Clinical evidence status:</b> Preclinical. Eugenol has cell-line and animal-model anticancer evidence, plus limited adjunctive clinical-context use in aromatherapy or topical/dental products, but there is no established clinical evidence supporting eugenol as a cancer treatment. Registry-visible oncology studies involving essential oils generally assess symptom support or mixtures, not purified eugenol as an anticancer therapeutic.</p>
<h3>Eugenol Cancer Mechanism Table</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Mitochondrial apoptosis and caspases</td>
<td>↑ Bax, ↑ cytochrome-c, ↑ caspase-3/8/9, ↓ Bcl-2, ↓ PARP integrity</td>
<td>Mixed; cytoprotection at low exposure but irritation/cytotoxicity at high exposure</td>
<td>R/G</td>
<td>Apoptotic tumour-cell killing</td>
<td>Core and most reproducible anticancer axis across breast, cervical, gastric, lung, and other models.</td>
</tr>
<tr>
<td>2</td>
<td>PI3K Akt mTOR survival signalling</td>
<td>↓ PI3K/Akt, ↓ mTOR signalling, ↑ FOXO3a activity, ↑ autophagy/apoptosis</td>
<td>Context-dependent</td>
<td>R/G</td>
<td>Reduced survival signalling and increased treatment vulnerability</td>
<td>Highly relevant in breast cancer and lung cancer models; may overlap with HER2/PI3K-Akt effects.</td>
</tr>
<tr>
<td>3</td>
<td>NF-κB COX-2 inflammatory signalling</td>
<td>↓ NF-κB, ↓ COX-2, ↓ inflammatory cytokine signalling</td>
<td>↓ inflammatory signalling in non-malignant inflammatory contexts</td>
<td>R/G</td>
<td>Anti-inflammatory and anti-survival transcriptional pressure</td>
<td>Important bridge between anticancer and general anti-inflammatory pharmacology.</td>
</tr>
<tr>
<td>4</td>
<td>MMP invasion and metastasis</td>
<td>↓ MMP-2, ↓ MMP-9, ↓ migration, ↓ invasion</td>
<td>Context-dependent</td>
<td>G</td>
<td>Anti-invasive and anti-metastatic activity</td>
<td>Mechanistically meaningful for breast, fibrosarcoma, gastric, and lung cancer models.</td>
</tr>
<tr>
<td>5</td>
<td>Angiogenesis and VEGF-linked signalling</td>
<td>↓ VEGF-linked angiogenic markers, ↓ invasion-associated vascular support</td>
<td>Context-dependent; excessive exposure may irritate tissues</td>
<td>G</td>
<td>Reduced tumour vascularization support</td>
<td>Best supported in animal carcinogenesis and metastasis-associated models rather than clinical oncology.</td>
</tr>
<tr>
<td>6</td>
<td>Cell cycle arrest</td>
<td>↑ p21, ↑ p27, ↓ cyclin-linked proliferation, S-phase or G2/M effects depending on model</td>
<td>Context-dependent</td>
<td>G</td>
<td>Reduced proliferation</td>
<td>Secondary but common contributor to antiproliferative activity.</td>
</tr>
<tr>
<td>7</td>
<td>Mitochondrial ROS redox stress</td>
<td>↑ ROS or redox stress in some cancer models; antioxidant effects in others</td>
<td>Often ↓ oxidative stress at low exposure; irritation or toxicity possible at high exposure</td>
<td>P/R/G</td>
<td>Context-dependent redox modulation</td>
<td>Do not tag simply as antioxidant. Cancer-cell effect can be pro-oxidant, antioxidant, or mixed depending on dose, timing, and model.</td>
</tr>
<tr>
<td>8</td>
<td>NRF2 antioxidant response</td>
<td>Mixed or context-dependent; not a primary anticancer-defining axis</td>
<td>Potential ↑ cytoprotective antioxidant response in non-malignant stress models</td>
<td>G</td>
<td>Secondary redox adaptation</td>
<td>Include only as secondary/contextual unless a specific study demonstrates NRF2-dependent cancer-cell modulation.</td>
</tr>
<tr>
<td>9</td>
<td>Glycolysis and metabolic reprogramming</td>
<td>Metabolomic shifts reported; likely ↓ proliferative metabolic fitness in selected CRC/oral cancer contexts</td>
<td>Unclear</td>
<td>G</td>
<td>Metabolic stress</td>
<td>Mechanistically interesting but less mature than apoptosis, PI3K/Akt, and invasion axes.</td>
</tr>
<tr>
<td>10</td>
<td>Chemosensitization</td>
<td>↑ cisplatin cytotoxicity, ↑ gemcitabine activity, ↑ apoptosis</td>
<td>Potential normal-cell toxicity not adequately defined</td>
<td>R/G</td>
<td>Adjunctive treatment sensitization</td>
<td>Preclinical only; promising but insufficient for clinical-use claims.</td>
</tr>
<tr>
<td>11</td>
<td>Radiosensitization</td>
<td>↑ ionizing-radiation cytotoxicity in cervical and oral cancer models</td>
<td>Normal-tissue protection versus sensitization remains unresolved</td>
<td>R/G</td>
<td>Radiation response enhancement</td>
<td>Preclinical only; should be tagged as experimental radiosensitizer, not clinically validated.</td>
</tr>
<tr>
<td>12</td>
<td>Clinical Translation Constraint</td>
<td>In-vitro exposure may exceed realistic free systemic levels</td>
<td>High-dose clove oil/eugenol can irritate mucosa and has overdose hepatotoxicity risk</td>
<td>G</td>
<td>Limits direct translation</td>
<td>Major constraints are rapid metabolism, dose-limited tolerability, formulation dependence, lack of oncology trials, and distinction between food-level GRAS use and therapeutic dosing.</td>
</tr>
</tbody>
</table>
<p>TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr</p>